Analysts say much of the problem can be traced back to government, with taxes now comprising the largest cost in the price of ...
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback